News

Albert Einstein College of Medicine researchers report that the composition of people’s gut bacteria may explain why some of them suffer life-threatening reactions after taking a key drug for treating metastatic colorectal cancer.

Here's an open invitation to steal. It goes out to cancer fighters and tempts them with a new program that predicts cancer drug effectiveness via machine learning and raw genetic data.

Investigators from Brigham and Women’s Hospital and Dana-Farber Cancer Institute are leveraging the power of artificial intelligence to develop a new technique to detect ovarian cancer early and accurately.

A new statistical model has enabled researchers to pinpoint 27 novel genes thought to prevent cancer from forming, in an analysis of over 2000 tumours across 12 human cancer types.

Based on this statistic, experts are now calling for the HPV test to replace cell smear testing (cytology) as a primary screening method for cervical cancer.

A study led by scientists from Harvard Medical School reveals “hidden” variability in how tumor cells are affected by anticancer drugs, offering new insights on why patients with the same form of cancer can have different responses to a drug.

Researchers have produced the first three-dimensional (3D) map of a molecular 'scaffold' called SgK223, known to play a critical role in the development and spread of aggressive breast, colon and pancreatic cancers.

Scientists have created a new class of antibody-drug conjugates (ADCs), using a versatile “double decker” technology that ties antibodies and a drug together to produce highly potent pharmaceuticals for cancer therapy.

Acquisition adds immuno-oncology capability to broaden Concept’s range of integrated drug discovery and development services.

Commercial team expands to build on R&D successes and drive Company growth.